Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Jul 05, 2021 9:52am
234 Views
Post# 33492319

RE:RE:RE:RE:RE:RE:Patient #16, #17 & #18

RE:RE:RE:RE:RE:RE:Patient #16, #17 & #18
riverrrow wrote: So no new patient data to look forward to in the upcoming newsletter. Hopefully all the patients that were cancer free in the last update continue to be cancer free. This trial study is progressing beyond excruciatingly slow. GLTA.



On March 25 they announced the launch of 6th U.S. site, on March 26 they announced the launch of the Anti Cancer Research Center, on April 9 they announced collaboration with the National Microbiology Laboratory on development of a coronavirus vaccine. On April 27 they put out the quarterly newsletter. Other than that it has been quiet "announcement wise" except for two financial quarterly reports. i.e. both May & June were quiet. 
<< Previous
Bullboard Posts
Next >>